Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
8.730
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET
March 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
March 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
March 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET
March 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
March 06, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
February 28, 2023
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary...
Via
TheNewswire.com
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
February 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
February 16, 2023
By Ernest Dela Aglanu, Benzinga
Via
TheNewswire.com
Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate
February 15, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023
February 02, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)
January 26, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering
January 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.